FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 260 filers reported holding FATE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,828,000 | -53.6% | 376,460 | +2.2% | 0.02% | -57.4% |
| Q3 2022 | $8,256,000 | +43.2% | 368,437 | +58.3% | 0.05% | +50.0% |
| Q2 2022 | $5,766,000 | -34.6% | 232,702 | +2.3% | 0.04% | -20.0% |
| Q1 2022 | $8,823,000 | -31.8% | 227,576 | +5.7% | 0.04% | -21.1% |
| Q4 2021 | $12,935,000 | -15.8% | 215,344 | -16.9% | 0.06% | -17.4% |
| Q3 2021 | $15,358,000 | -35.1% | 259,136 | -5.0% | 0.07% | -32.4% |
| Q2 2021 | $23,673,000 | +0.6% | 272,766 | -5.1% | 0.10% | -1.9% |
| Q1 2021 | $23,532,000 | – | 287,295 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |